New intraoperative probe for breast cancer tissue

Oncological probe for intraoperative identification of cancerous tissues during surgical treatment for breast cancer

High precision

The effectiveness of the probe has been confirmed in clinical studies conducted on several hundred patients

Real-time information

The device that allows intraoperative assessment of healthy tissue margins


Ergonomics and easy interpretation of results adapted to the surgeon's working conditions


Refined and repeatedly tested design made of high quality materials

How ONCOscanner works?

A probe is a device whose indications are related to the electrical properties (particularly permittivity and conductivity) that distinguish healthy and cancerous tissues. In the case of breast cancer, the dielectric properties of healthy tissue resembles fat tissue, and diseased breast tissue resembles muscle tissue.

Does the probe distinguish only between healthy and diseased breast tissue?

No. The method works well in those cases where there is a large difference in electrical properties between healthy and diseased tissue. This is especially true for breast cancer, presumably, the probe will be useful in the case of atherosclerosis (plaque calcification) or lymph nodes (including the cancer-affected sentinel nodes). In the case of breast cancer the equipment brings the most benefits so far.

Has the probe been tested in a clinical trial?

Our probe has been clinically tested by inventors on several hundred patients. The tests have shown that its application allows for correct identification of tumor tissues. Sensitivity and specificity were 93% and 87% respectively (193 samples from 70 patients). We thus demonstrated that we have developed a precise and easy-to-use device for intraoperative localization of breast cancer.

Why ONCOscanner?

Breast cancer is the most commonly occurring cancer among women and the second most common cancer overall. According to the World Health Organization (WHO) the number of new breast cancer cases in 2018 is estimated at the level of 2.1M. It means that every 15 seconds someone is diagnosed with breast cancer. Moreover, breast cancer is the 5th most common cause of death from cancer.

Since 2012 worldwide breast cancer incidence increased by more than 23% and mortality by 14%. Bearing that in mind, ONCOscanner deals with both societal and market issue.

The main goal of breast conserving surgery (BCS) is the complete removal of cancer with clear surgical margins while maintaining the natural shape of the breast. However, there is a conflict between obtaining an adequate excision margin around the tumor and not removing too much tissue, which may result in breast deformity. Currently, about 20-30% of patients require reoperation after a BCS, what contributes to: decreased patient satisfaction, increased health care costs and poorer cosmetic results. ONCOscanner will decrease this percentage, as it enables the surgeon to better recognise which sections of tissue still need to be removed.


Kazimierz Orzechowski, PhD

Principal Investigator

Learn more

Marek Rząca, MD

Oncologic Surgeon

Learn more

Stanisław Baj

Main Engineer & Designer

Learn more

Marcin Łuczyn


Learn more


The ONCOscanner team is scientifically affiliated with:

Provincial Specialist Hospital in Wrocław

Research and Development Centre

Learn more

University of Wrocław

Faculty of Chemistry

Learn more

Become an ONCOscanner partner!

We are looking for:

  • partners to distribute medical devices operating in the field of oncological surgery,
  • investors interested in capital support of our company within the next investment round intended for market launch of the probe.

If you are interested please contact us at biuro@oncoscanner.com.


Thank you!

The message has been sent.

Please fill out the form below or write to biuro@oncoscanner.com.

The message failed to send. Please try again or write to biuro@oncoscanner.com.

Onco Scanner Sp. z o.o.

al. Kasztanowa 3A
53-125 Wrocław

NIP: 8992820347